The Foundation for Sarcoidosis Research (FSR) has welcomed seven new institutions, including its first international member, into its FSR Global Sarcoidosis Clinic Alliance (FSR-GSCA), expanding a growing network of members dedicated to improving care for people living with sarcoidosis. Launched in 2022, the FSR-GSCA brings together leading…
News
Elevated levels of a blood protein called high-sensitivity cardiac troponin T (hs-cTnT) are associated with an increased risk of death and other adverse outcomes in people with cardiac sarcoidosis, and using a “simple, widely available blood test” measuring these levels to assess risk “could improve how we assess risk…
A mobile health app designed to guide breathing awareness meditation (BAM) sessions may effectively reduce fatigue and stress and improve the quality of life for people with sarcoidosis. That’s according to results from a pilot clinical trial (NCT05230693) that assessed the feasibility and efficacy of the Sarcoidosis Patient…
Sarcoidosis can significantly affect day-to-day life, and commonly used treatments may carry substantial risks of side effects, according to a report from the Foundation for Sarcoidosis Research (FSR). The report also finds that clinical trials testing new sarcoidosis treatments often do not fully reflect patient priorities, highlighting…
In people with cardiac sarcoidosis, patterns of signs and symptoms seen when the person is diagnosed can help predict the risk of long-term outcomes, including hospitalization and death, a new study shows. “The clinical phenotype [profile] of CS is a useful prognostic indicator,” researchers wrote, adding that these findings…
Among second-line treatments for sarcoidosis, methotrexate is safer and associated with a lower risk of hospitalization, intensive care, the need for breathing support, and death compared to mycophenolate mofetil (MMF), according to a large real-world study. Methotrexate also showed a trend toward better efficacy and similar safety…
The Foundation for Sarcoidosis Research (FSR) brought together more than 40 leading clinicians and researchers from around the world for an in-person meeting of the FSR Global Sarcoidosis Clinic Alliance (FSR-GSCA) and the FSR Sarcoidosis Biomarker Summit. Together, these two gatherings marked a major step forward in international collaboration…
Researchers have identified 12 genes linked to chronic inflammation, immune dysregulation, and lung scarring that appear to be shared across both sarcoidosis and lung cancer. These genes were also tied to the Wnt signaling pathway, a system that helps regulate immune response and cell growth. Based on these findings,…
Only about one in four patients with unexplained, life-threatening arrhythmias are tested for cardiac sarcoidosis, even though medical guidelines call for it, according to a large worldwide study. As a result, cardiac sarcoidosis remains largely underdiagnosed, a problem that “carries significant risks, including delayed treatment and the potential for…
Combining angiotensin receptor blockers or ARBs — a type of medication used to lower blood pressure — with a class of diabetes medications called SGLT-2 inhibitors may help improve survival in adults with sarcoidosis, according to the findings of a new U.S. study. Data showed that the simultaneous use…
Recent Posts
- 7 new institutions join FSR alliance to improve treatment of sarcoidosis
- Simple blood test may predict cardiac sarcoidosis outcomes
- To scoot or not to scoot: Using a mobility aid with a dynamic disability
- Mobile app for breathing meditation may reduce sarcoidosis fatigue
- New report highlights unmet needs and treatment burdens in sarcoidosis
- Cardiac sarcoidosis symptoms at diagnosis help predict long-term risk
- Methotrexate is safer second-line sarcoidosis treatment than MMF
- A holiday gift guide for your loved one with sarcoidosis
- FSR gathers global leaders to drive progress in sarcoidosis research
- New genetic clues connect sarcoidosis with lung cancer risk